Status:
COMPLETED
A Two Week Study to Assess the Tolerability of AZD9668 in Chronic Obstructive Pulmonary Disease (COPD) Patients
Lead Sponsor:
AstraZeneca
Conditions:
Chronic Obstructive Pulmonary Disease (COPD)
Eligibility:
All Genders
40-80 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to assess the tolerability (effect of drug on body) and pharmacokinetics (effect of body on drug) of AZD9668 in patients with mild to moderate COPD
Eligibility Criteria
Inclusion
- Mild to moderate COPD
- Smokers or ex-smokers
- post-menopausal females
Exclusion
- Past history or current evidence of clinically significant heart disease
- Lung disease other than COPD
- Treatment with systemic steroids within 8 weeks of study visit 2
- Treatment with antibiotics within 4 weeks of study visit 1 or study visit 2
Key Trial Info
Start Date :
June 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2008
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT00703391
Start Date
June 1 2008
End Date
September 1 2008
Last Update
January 26 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Berlin, Germany